Clinical Trial

Propolis for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer

Completed
View on ClinicalTrials.gov →
Summary
This clinical trial evaluated whether a 15% propolis solution could delay or prevent severe oral mucositis in patients with head and neck cancer receiving radiotherapy or concurrent chemoradiotherapy. Oral mucositis is a common and painful side effect of radiotherapy to the head and neck region. It can interfere with eating, swallowing, hydration, pain control, and treatment tolerance. Researchers compared propolis plus standard oral care with placebo plus standard oral care. The main question was whether propolis delayed the first occurrence of severe oral mucositis during radiotherapy. Severe oral mucositis was assessed using the World Health Organization Oral Toxicity Scale. Participants were randomly assigned to receive either 15% propolis solution or placebo. Both solutions were used with the same schedule. Participants diluted 20 drops in 50 mL water and used the assigned solution with a swish-and-swallow method four times daily during radiotherapy. All participants also received standard oral care. Participants had weekly clinical assessments during radiotherapy. Researchers recorded oral mucositis grade, swallowing difficulty, pain, need for oral nutritional supplements, clinical oral candidiasis, hospitalization for supportive care, and other treatment-related outcomes. Quality-of-life questionnaires were completed at planned study visits.
Trial Details
NCT Number NCT07597525
Lead Sponsor Ankara Oncology Research and Training Hospital
Conditions Oral Mucositis in Head and Neck Cancer
Enrollment 140 participants
Start Date 2019-05-27
Primary Completion 2025-09-26 (estimated)
Study Completion 2025-09-26 (estimated)
Updated on ClinicalTrials.gov 2026-05-19